NO20032271D0 - GABA-enhancere i behandlingen av sykdommer relatert til redusert nevrosteroidaktivitet - Google Patents

GABA-enhancere i behandlingen av sykdommer relatert til redusert nevrosteroidaktivitet

Info

Publication number
NO20032271D0
NO20032271D0 NO20032271A NO20032271A NO20032271D0 NO 20032271 D0 NO20032271 D0 NO 20032271D0 NO 20032271 A NO20032271 A NO 20032271A NO 20032271 A NO20032271 A NO 20032271A NO 20032271 D0 NO20032271 D0 NO 20032271D0
Authority
NO
Norway
Prior art keywords
treatment
diseases related
gaba
enhancers
activity
Prior art date
Application number
NO20032271A
Other languages
English (en)
Other versions
NO20032271L (no
Inventor
Bjarke Ebert
Peter Hoengaard Andersen
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8159857&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20032271(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of NO20032271D0 publication Critical patent/NO20032271D0/no
Publication of NO20032271L publication Critical patent/NO20032271L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
NO20032271A 2000-11-20 2003-05-20 GABA-enhancere i behandlingen av sykdommer relatert til redusert nevrosteroidaktivitet NO20032271L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200001743 2000-11-20
PCT/DK2001/000773 WO2002040009A1 (en) 2000-11-20 2001-11-20 Gaba enhancers in the treatment of diseases relating to reduced neurosteroid activity

Publications (2)

Publication Number Publication Date
NO20032271D0 true NO20032271D0 (no) 2003-05-20
NO20032271L NO20032271L (no) 2003-05-20

Family

ID=8159857

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20032271A NO20032271L (no) 2000-11-20 2003-05-20 GABA-enhancere i behandlingen av sykdommer relatert til redusert nevrosteroidaktivitet

Country Status (33)

Country Link
US (2) US20040024038A1 (no)
EP (1) EP1337247B1 (no)
JP (1) JP4152186B2 (no)
KR (1) KR100865651B1 (no)
CN (1) CN1318027C (no)
AR (1) AR031473A1 (no)
AT (1) ATE336242T1 (no)
AU (2) AU2351402A (no)
BG (1) BG107909A (no)
BR (1) BR0115668A (no)
CA (1) CA2429220C (no)
CY (1) CY1106209T1 (no)
CZ (1) CZ20031383A3 (no)
DE (1) DE60122368T2 (no)
DK (1) DK1337247T3 (no)
EA (1) EA007287B1 (no)
ES (1) ES2266308T3 (no)
HR (1) HRP20030404A2 (no)
HU (1) HUP0400505A3 (no)
IL (1) IL155587A0 (no)
IS (1) IS2427B (no)
ME (1) MEP6408A (no)
MX (1) MXPA03004349A (no)
NO (1) NO20032271L (no)
NZ (1) NZ525520A (no)
PL (1) PL361051A1 (no)
PT (1) PT1337247E (no)
SI (1) SI1337247T1 (no)
SK (1) SK7682003A3 (no)
UA (1) UA77403C2 (no)
WO (1) WO2002040009A1 (no)
YU (1) YU39003A (no)
ZA (1) ZA200303289B (no)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
CN1615146A (zh) * 2001-11-26 2005-05-11 芬策尔贝格有限两合公司 生姜提取物制剂
EP1641456B1 (en) * 2003-06-25 2010-03-03 H. Lundbeck A/S Gaboxadol for treating depression and other affective disorders
GB0402118D0 (en) 2004-01-30 2004-03-03 Merck Sharp & Dohme Polymorphic forms of a GABAA agonist
AU2004324938A1 (en) * 2004-06-29 2006-05-26 H. Lundbeck A/S Treatment of neuropathic pain, fibromyalgia or rheumatoid arthritis
WO2006012563A2 (en) * 2004-07-23 2006-02-02 The Regents Of The University Of California Method for the treatment and diagnosis of certain psychiatric disorders related to the menstrual cycle
GB0417558D0 (en) * 2004-08-06 2004-09-08 Merck Sharp & Dohme Novel combination therapy
EP1848420A4 (en) 2005-01-28 2008-01-23 Merck & Co Inc POLYMORPH SHAPES OF A GABAA AGONIST
US20070122507A1 (en) * 2005-05-26 2007-05-31 Palu Afa K Histone deacetylase and tumor necrosis factor converting enzyme inhibition
US9209995B2 (en) * 2006-12-29 2015-12-08 Prodea Systems, Inc. Presence status notification from digital endpoint devices through a multi-services gateway device at the user premises
WO2008141112A1 (en) * 2007-05-09 2008-11-20 Cenerx Biopharma, Inc. Methods of treating rett syndrome
CN101585862B (zh) * 2008-05-20 2014-12-17 梅克芳股份公司 甾族化合物
CN103547240B (zh) * 2011-06-16 2016-03-30 索雷斯生命科学公司 用于人类自主神经系统的平衡和维持健康的系统和方法
RU2496496C1 (ru) * 2012-10-04 2013-10-27 Исаак Григорьевич Гитлин Фармацевтическая композиция, обладающая гамк-ергической активностью
KR20240160666A (ko) 2015-07-17 2024-11-11 오비드 테라퓨틱스 인크. 가복사돌로 발달장애들을 치료하는 방법들
EP4233861A3 (en) * 2016-08-11 2023-10-11 Ovid Therapeutics, Inc. Compositions for treatment of essential tremor
US20180338959A1 (en) * 2017-05-24 2018-11-29 Ovid Therapeutics Inc. Treatment of depressive disorders
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
KR102049522B1 (ko) * 2018-06-05 2019-11-27 충남대학교산학협력단 Gaba를 유효성분으로 하는 살모넬라 감염질환의 예방 및 치료용 조성물
KR102049526B1 (ko) * 2018-06-05 2019-11-27 충남대학교산학협력단 Gaba를 유효성분으로 하는 항결핵 약학 조성물
AU2019345312A1 (en) 2018-09-20 2021-03-25 Ovid Therapeutics Inc. Use of gaboxadol for the treatment of tourette syndrome, tics and stuttering
WO2020106927A1 (en) 2018-11-21 2020-05-28 Certego Therapeutics Gaboxadol for reducing risk of suicide and rapid relief of depression
CN113423399A (zh) 2018-12-17 2021-09-21 奥维德医疗公司 加波沙朵用于治疗非24小时睡眠-觉醒障碍的用途
JP2022529781A (ja) 2019-04-17 2022-06-24 コンパス パスファインダー リミテッド サイロシビンによるうつ病及び他の様々な障害の治療
WO2021127308A1 (en) 2019-12-18 2021-06-24 Ovid Therapeutics Inc. GABOXADOL FOR THERAPEUTIC TREATMENT OF 1p36 DELETION SYNDROME
MX2022014599A (es) 2020-05-20 2022-12-16 Certego Therapeutics Inc Gaboxadol deuterado en anillo y su uso para el tratamiento de trastornos psiquiatricos.
CN114404437A (zh) * 2022-03-15 2022-04-29 山东中医药大学 没食子酰芍药苷在制备gabaa受体抑制剂中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4362731A (en) * 1980-09-01 1982-12-07 Sandoz Ltd. Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof
US5120723A (en) * 1987-08-25 1992-06-09 University Of Southern California Method, compositions, and compounds for modulating brain excitability
JPH06510999A (ja) * 1991-09-13 1994-12-08 コセンシス・インコーポレイテッド ステロイド結合部位を有する新規ＧＡＢＡ↓ａレセプター
US5206415A (en) * 1991-12-20 1993-04-27 Washington University Tricyclic steroid analogs
CZ300694A3 (en) * 1993-12-02 1996-05-15 Akzo Nobel Nv Substituted 2beta-morpholinandrostane derivatives, process of their preparation, their use for preparing pharmaceutical preparations and pharmaceutical compositions containing thereof
AP653A (en) * 1994-11-23 1998-07-21 Cocensys Inc Androstane and pregnane series for allosteric modulations of gaba receptor.
US5776959A (en) * 1995-06-05 1998-07-07 Washington University Anticonvulsant and anxiolytic lactam and thiolactam derivatives
EP1288220A3 (en) * 1995-06-06 2004-07-21 Euro-Celtique Neuroactive 3.alpha.-hydroxy-steroids of the androstane and pregnane series
IT1290003B1 (it) * 1997-03-03 1998-10-19 Angelini Ricerche Spa Uso di pivagabina per preparare composizioni farmaceutiche
GB9801208D0 (en) * 1998-01-21 1998-03-18 Merck Sharp & Dohme Therapeutic agents
KR100599142B1 (ko) * 1998-07-22 2006-07-12 악조 노벨 엔.브이. α- 아미노산 페닐 에스테르 유도체
AU1808401A (en) * 1999-12-08 2001-06-18 Warner-Lambert Company Method for the stereoselective synthesis of cyclic amino acids

Also Published As

Publication number Publication date
CY1106209T1 (el) 2011-06-08
US20090143435A1 (en) 2009-06-04
AU2002223514B2 (en) 2006-11-30
PL361051A1 (en) 2004-09-20
IS6803A (is) 2003-04-30
EA200300594A1 (ru) 2003-10-30
AU2351402A (en) 2002-05-27
PT1337247E (pt) 2006-11-30
SK7682003A3 (en) 2003-10-07
MEP6408A (xx) 2010-02-10
MXPA03004349A (es) 2003-08-19
EP1337247A1 (en) 2003-08-27
ES2266308T3 (es) 2007-03-01
CN1318027C (zh) 2007-05-30
ZA200303289B (en) 2005-07-27
CZ20031383A3 (cs) 2003-08-13
SI1337247T1 (sl) 2006-12-31
US20040024038A1 (en) 2004-02-05
IL155587A0 (en) 2003-11-23
ATE336242T1 (de) 2006-09-15
IS2427B (is) 2008-10-15
BR0115668A (pt) 2003-09-02
DE60122368T2 (de) 2007-08-09
KR100865651B1 (ko) 2008-10-29
HUP0400505A3 (en) 2008-08-28
HK1075010A1 (en) 2005-12-02
CN1592616A (zh) 2005-03-09
DE60122368D1 (de) 2006-09-28
WO2002040009A1 (en) 2002-05-23
YU39003A (sh) 2006-05-25
AR031473A1 (es) 2003-09-24
EP1337247B1 (en) 2006-08-16
BG107909A (bg) 2004-08-31
JP2004513921A (ja) 2004-05-13
NZ525520A (en) 2005-04-29
CA2429220C (en) 2009-09-15
CA2429220A1 (en) 2002-05-23
HRP20030404A2 (en) 2005-04-30
NO20032271L (no) 2003-05-20
DK1337247T3 (da) 2006-12-04
JP4152186B2 (ja) 2008-09-17
HUP0400505A2 (hu) 2004-07-28
KR20030065517A (ko) 2003-08-06
EA007287B1 (ru) 2006-08-25
UA77403C2 (en) 2006-12-15

Similar Documents

Publication Publication Date Title
AU2351402A (en) Gaba enhancers in the treatment of diseases relating to reduced neurosteroid activity
IS8913A (is) Afleiður 4-tetrazólýl-4-fenýlpiperidíns til þess að meðhöndla verk
NO20053077D0 (no) Terapeutiske formuleringer for behandling av beta-amyloid-relaterte sykdommer.
NO20031442D0 (no) Morfolin-acetamidderivater for behandling av inflammatoriske sykdommer
PT966447E (pt) Moleculas pequenas uteis no tratamento de doencas inflamatorias
ATE516037T1 (de) Topische formulierung von ivermectin zur behandlung von dermatologischen erkrankungen
DE60124302D1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
IS8371A (is) Notkun breyttra sýklósporína til að meðhöndla HCVsjúkdóma
NO20031443L (no) Forbindelser nyttige for behandling av inflammatoriske sykdommer
EP1727530A4 (en) TOPICAL FORMULATIONS FOR THE TREATMENT OF SKIN DISEASES
NO20026222L (no) Fremgangsmåte til å behandle neutrofilrelaterte sykdommer med topiske anestesimidler
IS6575A (is) Hýdroxýfenýl-píperidín-4-ýlíden-metýl-bensamíðafleiður til að meðhöndla sársauka
DK1487828T3 (da) Morpholinyl-urea-derivater til anvendelse til behandling af inflammatoriske sygdomme
EP1560572A4 (en) TOPICAL PARASITICIDE FORMULATIONS AND TREATMENT PROCEDURES
DE50013843D1 (de) Arzneimittel zur behandlung von darmerkrankungen
IL166016A0 (en) Topical treatment of skin diseases
EP1512405A4 (en) COMPOSITION TO TREAT CHLOASMA AND COMPOSITION TO REDUCE MUTUAL APPEARANCE
AU2727701A (en) Nitroglycerin ointment for treatment of pain associated with anal disease
IS6563A (is) Hýdroxýfenýl-píperasinýl-metýl-bensamíðafleiður til að meðhöndla sársauka
IS6574A (is) Kínólinýl-píperidín-4-ýlíden-metýl-bensamíðafleiður til að meðhöndla sársauka
DE60315490D1 (de) Therapeutische behandlung
DK1503747T3 (da) Diclofenacbaseret sammensætning til topisk behandling af sygdomme
ATE345123T1 (de) Behandlung von angiogenesebezogenen krankheiten mit benzoyl phenylessigsäure derivaten
NO20014081D0 (no) Anvendelse av tianeptin i produksjonen av medikamenter til behandling av nevrodegenerative patologier
NO20030762L (no) Forbedret spesifisitet i behandling av sykdommer

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: PLOUGMANN & VINGTOFT, POSTBOKS 1003 SENTRUM, 0104

FC2A Withdrawal, rejection or dismissal of laid open patent application